UY23561A1 - Procedimiento para la preparacion de tnf-muteinas - Google Patents
Procedimiento para la preparacion de tnf-muteinasInfo
- Publication number
- UY23561A1 UY23561A1 UY23561A UY23561A UY23561A1 UY 23561 A1 UY23561 A1 UY 23561A1 UY 23561 A UY23561 A UY 23561A UY 23561 A UY23561 A UY 23561A UY 23561 A1 UY23561 A1 UY 23561A1
- Authority
- UY
- Uruguay
- Prior art keywords
- mutein
- necrosis factor
- tumor necrosis
- human tumor
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Procedimiento para la preparación de una muteína del factor de necrosis tumoral humano o una sal farmacéuticamente aceptable de la misma, que tiene una afinidad de unión selectiva para el receptor del factor de necrosis tumoral humano p55, esta muteína se caracteriza porque la secuencia de aminoácidos del factor de necrosis tumoral humano se ha cambiado como mínimo en la posición 86 mostrando un resto de treonina en lugar de un resto de serina También es de alcance una secuencia de ADN que codifica dicha luteína, un vector que comprende dicha secuencia de ADN, una célula hospedadora transformada mediante dicho vector. La muteína según lo descrito y sus composiciones farmacéuticas son de utilidad en el tratamiento de enfermedades.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92810249 | 1992-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY23561A1 true UY23561A1 (es) | 1993-09-20 |
Family
ID=8211902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY23561A UY23561A1 (es) | 1992-04-02 | 1993-03-31 | Procedimiento para la preparacion de tnf-muteinas |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5486463A (es) |
| EP (1) | EP0563714A3 (es) |
| JP (1) | JPH07285997A (es) |
| CN (1) | CN1037844C (es) |
| AU (1) | AU659927B2 (es) |
| BR (1) | BR9301420A (es) |
| CA (1) | CA2091313A1 (es) |
| CZ (1) | CZ283533B6 (es) |
| FI (1) | FI931488L (es) |
| HU (1) | HUT69790A (es) |
| IL (1) | IL105170A0 (es) |
| MX (1) | MX9301700A (es) |
| NO (1) | NO931141L (es) |
| NZ (1) | NZ247265A (es) |
| PL (1) | PL298345A1 (es) |
| SK (1) | SK376492A3 (es) |
| TW (1) | TW260707B (es) |
| UY (1) | UY23561A1 (es) |
| ZA (1) | ZA932177B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR970005042B1 (ko) * | 1993-02-09 | 1997-04-11 | 한일합성섬유공업 주식회사 | 종양괴사인자-알파 뮤테인 |
| CA2119089A1 (en) * | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
| CN1049663C (zh) * | 1994-09-01 | 2000-02-23 | 中国科学院上海生物工程研究中心 | 突变的人肿瘤坏死因子 |
| US7070771B1 (en) | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
| US20020077276A1 (en) * | 1999-04-27 | 2002-06-20 | Fredeking Terry M. | Compositions and methods for treating hemorrhagic virus infections and other disorders |
| US6379708B1 (en) * | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
| DK1666052T3 (da) * | 2000-02-16 | 2011-09-12 | Genentech Inc | Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer |
| EA007984B1 (ru) * | 2001-08-03 | 2007-02-27 | Дженентек, Инк. | ПОЛИПЕПТИДЫ TACIs И BR3 И ИХ ПРИМЕНЕНИЕ |
| US7786282B2 (en) * | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
| US20030199024A1 (en) * | 2002-04-19 | 2003-10-23 | Hansen Ted H. | Single chain trimers of class I MHC molecules |
| MXPA05000940A (es) * | 2002-07-25 | 2005-05-16 | Genentech Inc | Anticuerpos taci y su uso. |
| EP1578799B8 (en) * | 2002-12-02 | 2011-03-23 | Amgen Fremont Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| US20040121971A1 (en) * | 2002-12-20 | 2004-06-24 | Gang Chen | Therapeutic use of tumor necrosis factor-alpha mutein |
| US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
| EP2272868B1 (en) * | 2003-06-05 | 2015-03-04 | Genentech, Inc. | Combination therapy for B cell disorders |
| CN100390200C (zh) * | 2003-11-24 | 2008-05-28 | 中国医学科学院基础医学研究所 | 一种用于治疗获得性免疫缺陷综合征的重组靶向融合蛋白 |
| TW201122103A (en) * | 2004-01-06 | 2011-07-01 | Hayashibara Biochem Lab | Tnf antagonists and tnf inhibitors comprising the same as the active ingredient |
| CN1752211B (zh) * | 2004-09-23 | 2010-09-15 | 中国医学科学院基础医学研究所 | 用于治疗获得性免疫缺陷综合征的重组靶向融合蛋白 |
| GB0425972D0 (en) | 2004-11-25 | 2004-12-29 | Celltech R&D Ltd | Biological products |
| US7850960B2 (en) | 2004-12-30 | 2010-12-14 | University Of Washington | Methods for regulation of stem cells |
| US20070065514A1 (en) * | 2005-09-22 | 2007-03-22 | Howell Mark D | Method for enhancing immune responses in mammals |
| AU2006318539B2 (en) * | 2005-11-23 | 2012-09-13 | Genentech, Inc. | Methods and compositions related to B cell assays |
| US8518697B2 (en) * | 2006-04-04 | 2013-08-27 | Washington University | Single chain trimers and uses therefor |
| US20100316626A1 (en) * | 2006-08-11 | 2010-12-16 | The Government Of The United States Of America As Represented By The Secretary | Methods for treatment and diagnosis of psychiatric disorders |
| WO2008127515A1 (en) * | 2007-03-01 | 2008-10-23 | Cytologic, Inc. | Compositions and method for enhancing immune responses in mammals |
| US9821010B2 (en) | 2013-02-07 | 2017-11-21 | The General Hospital Corporation | Methods for expansion or depletion of T-regulatory cells |
| US11224858B1 (en) | 2020-10-01 | 2022-01-18 | Immunicom, Inc. | Reduced leaching of a ligand |
| AU2020470781A1 (en) | 2020-10-01 | 2023-05-18 | Immunicom, Inc. | Reduced leaching of a ligand |
| WO2025163107A1 (en) | 2024-02-01 | 2025-08-07 | Institut Gustave Roussy | Immune cells defective for znf217 and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07106158B2 (ja) * | 1986-12-04 | 1995-11-15 | サントリー株式会社 | 抗腫瘍活性を有する新規ポリペプチドおよびその製造法 |
| CA2055168A1 (en) * | 1990-11-21 | 1992-05-22 | Walter Fiers | Tnf-muteins |
-
1992
- 1992-12-18 CZ CS923764A patent/CZ283533B6/cs unknown
- 1992-12-18 SK SK3764-92A patent/SK376492A3/sk unknown
-
1993
- 1993-02-25 TW TW082101370A patent/TW260707B/zh active
- 1993-03-09 CA CA002091313A patent/CA2091313A1/en not_active Abandoned
- 1993-03-20 EP EP19930104591 patent/EP0563714A3/en not_active Withdrawn
- 1993-03-24 HU HU9300843A patent/HUT69790A/hu unknown
- 1993-03-26 NZ NZ247265A patent/NZ247265A/en unknown
- 1993-03-26 NO NO93931141A patent/NO931141L/no unknown
- 1993-03-26 ZA ZA932177A patent/ZA932177B/xx unknown
- 1993-03-26 MX MX9301700A patent/MX9301700A/es unknown
- 1993-03-26 IL IL105170A patent/IL105170A0/xx unknown
- 1993-03-30 AU AU35611/93A patent/AU659927B2/en not_active Ceased
- 1993-03-31 UY UY23561A patent/UY23561A1/es unknown
- 1993-04-01 CN CN93103419A patent/CN1037844C/zh not_active Expired - Fee Related
- 1993-04-01 JP JP5075445A patent/JPH07285997A/ja active Pending
- 1993-04-01 FI FI931488A patent/FI931488L/fi unknown
- 1993-04-01 PL PL29834593A patent/PL298345A1/xx unknown
- 1993-04-01 US US08/041,648 patent/US5486463A/en not_active Expired - Fee Related
- 1993-04-02 BR BR9301420A patent/BR9301420A/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO931141L (no) | 1993-10-04 |
| ZA932177B (en) | 1993-10-04 |
| FI931488A7 (fi) | 1993-10-03 |
| SK376492A3 (en) | 1995-06-07 |
| CZ376492A3 (en) | 1994-01-19 |
| EP0563714A3 (en) | 1993-11-10 |
| TW260707B (es) | 1995-10-21 |
| BR9301420A (pt) | 1993-10-05 |
| MX9301700A (es) | 1993-10-29 |
| NO931141D0 (no) | 1993-03-26 |
| US5486463A (en) | 1996-01-23 |
| CN1037844C (zh) | 1998-03-25 |
| JPH07285997A (ja) | 1995-10-31 |
| AU659927B2 (en) | 1995-06-01 |
| HUT69790A (en) | 1995-09-28 |
| FI931488A0 (fi) | 1993-04-01 |
| NZ247265A (en) | 1995-10-26 |
| PL298345A1 (en) | 1993-12-27 |
| HU9300843D0 (en) | 1993-06-28 |
| CN1079225A (zh) | 1993-12-08 |
| EP0563714A2 (en) | 1993-10-06 |
| AU3561193A (en) | 1993-10-07 |
| FI931488L (fi) | 1993-10-03 |
| IL105170A0 (en) | 1993-07-08 |
| CZ283533B6 (cs) | 1998-04-15 |
| CA2091313A1 (en) | 1993-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY23561A1 (es) | Procedimiento para la preparacion de tnf-muteinas | |
| ES2147553T3 (es) | Vectores virales recombinantes para la expresion en unas celulas musculares. | |
| EA200300381A1 (ru) | Нуклеиновые кислоты и полипептиды нового рецептора | |
| BR9812048A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos de tratar uma doença mediada por uma cinase, de tratar a rejeição no transplante de órgão, e de tratar a alopecia induzida pela quimioterapia | |
| BR9912448A (pt) | Composto, composição farmacêutica, e, processos de indução de biossìntese de citoquina em um mamìfero, de tratamento de uma doença virótica em um mamìfero, e de tratamento de uma doença neoplásica em um mamìfero | |
| AR003087A1 (es) | PROTEINAS OBESAS RECOMBINANTES (Oh), VECTOR DE EXPRESION, PROTEINA DE FUSION, SECUENCIA DE ADN, METODO PARA PRODUCIR DICHAS PROTEINAS, COMPOSICIONQUE LAS COMPRENDE, EMPLEO DE DICHAS PROTEINAS Y METODO DE TRATAMIENTO. | |
| PT73161A (fr) | Procede pour la preparation de derives de n-(vynblastinoyl-23) aux amino-acids et peptides et son application terapeutique | |
| ES8703490A1 (es) | Un procedimiento para producir un polipeptido que tiene o contiene un polipeptido de factor de necrosis de tumor humano | |
| ES2174855T3 (es) | Metodos diagnosticos y composiciones farmaceuticas que se basan en proteinas notch y acidos nucleicos. | |
| CA2122714A1 (en) | Materials comprising and methods of preparation and use for ribosome-inactivating proteins | |
| AR247590A1 (es) | Una secuencia de adn que codifica derivados de factor viii humano recombinante y un procedimiento para su obtencion | |
| ES2153367T3 (es) | Derivados de clorofila y de bacterioclorofila, su preparacion y composiciones farmaceuticas que los contienen. | |
| DE68916932D1 (de) | Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus. | |
| BR9507073A (pt) | Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto | |
| HUT66309A (en) | Bpc peptides, their preparation and therapeutic use | |
| AR013529A1 (es) | Rantes amino-terminalmente truncado, moleculas de adn, vector de expresion, celula huesped, proceso recombinante para prepararlo, su uso para preparar un medicamento y composicion farmaceutica que lo comprende. | |
| ES2053454T3 (es) | Composiciones farmaceuticas que contienen peptidos del grupo de la colecistoquinina-ceruleina para la terapia de estados de shock y de insuficiencias respiratorias y cardiocirculatorias. | |
| AR020329A1 (es) | UNA SUSTANCIA, EN PARTICULAR UNA RIBOZIMA, CAPAZ DE INHIBIR LA EXPRESION DE PRESENILINA 2, UNA MOLECULA DE DNA RECOMBINANTE QUE CODIFICA DICHA RIBOZIMA, UNVECTOR RECOMBINANTE QUE COMPRENDE EL cDNA CORRESPONDIENTE A DICHA RIBOZIMA, UNA CELULA HOSPEDADORA QUE COMPRENDE DICHO VECTOR RECOMBINANTE, UNA C | |
| NZ508816A (en) | Bactericidal/permeability-increasing protein (BPI) deletion analogs | |
| EP0417003A3 (en) | Use of antiprogestomimetics for stimulating ovulation | |
| ES2114555T3 (es) | Nuevo interferon gamma humano recombinado. | |
| ATE310828T1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
| AR010924A1 (es) | Azapeptidos ciclicos, sus enantiomeros y diastereomeros, un procedimiento para su preparacion, su empleo para preparar un medicamento, las preparacionesfarmaceuticas que los contienen y un procedimiento para obtener estas preparaciones farmaceuticas. | |
| AR014884A1 (es) | Uso de un conjugado de angiotensina inmunogenico y composicion farmaceutica | |
| AR013886A1 (es) | Proteinas utiles para tratar la obesidad y condiciones asociadas con la obesidad; composiciones farmaceuticas formuladas con dichas proteinas;compuestos polinucleoticos de dna que codifican dichas proteinas y procedimiento para pepararlas |